Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 4:28 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 38 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Norovirus Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Dose-Optimization Trial of VXA-G1.1-NN in Healthy Volunteers

NCT03125473
View directory record Official record
Conditions
Norovirus Gastroenteritis
Interventions
VXA-G1.1-NN Oral Vaccine
Biological
Lead sponsor
Vaxart
Industry
Eligibility
19 Years to 49 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated May 29, 2018 · Synced Sep 3, 2026, 4:28 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of Norovirus GI.1/GII.4 Bivalent Virus-Like Particle Vaccine in an Elderly Population

NCT02661490
View directory record Official record
Conditions
Norovirus
Interventions
Norovirus GI.1/GII.4 Bivalent VLP Vaccine, 0.9% sodium chloride (saline)
Biological · Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
320 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
10
States / cities
Birmingham, Alabama • Fountain Hills, Arizona • Littleton, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated May 17, 2020 · Synced Sep 3, 2026, 4:28 PM EDT
Completed Phase 2 Interventional Results available

NNITS-Nitazoxanide for Norovirus in Transplant Patients Study

NCT03395405
View directory record Official record
Conditions
Gastroenteritis Norovirus
Interventions
Nitazoxanide, Placebo
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Years to 99 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
12
States / cities
Chicago, Illinois • Kansas City, Kansas • Baltimore, Maryland + 6 more
Source: ClinicalTrials.gov public record
Updated May 20, 2025 · Synced Sep 3, 2026, 4:28 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Serologic Assay Validation and Proficiency Testing of HIL-214 in Adults

NCT05972733
View directory record Official record
Conditions
Gastroenteritis
Interventions
HIL-214
Biological
Lead sponsor
HilleVax
Industry
Eligibility
18 Years to 49 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
2
States / cities
Rolling Hills Estates, California • Stockbridge, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 18, 2025 · Synced Sep 3, 2026, 4:28 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Phase I Norovirus Challenge Model

NCT04174560
View directory record Official record
Conditions
Gastroenteritis Norovirus
Interventions
Norovirus GII.4 Challenge Pool
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 5, 2025 · Synced Sep 3, 2026, 4:28 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1 Norwalk Vaccine Study

NCT00806962
View directory record Official record
Conditions
Norovirus
Interventions
Adjuvant/Excipients, placebo, Norwalk VLP Vaccine
Drug · Device · Biological
Lead sponsor
LigoCyte Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
4
States / cities
Baltimore, Maryland • St Louis, Missouri • Rochester, New York + 1 more
Source: ClinicalTrials.gov public record
Updated May 5, 2015 · Synced Sep 3, 2026, 4:28 PM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CDI-988 in Healthy Adults After Challenge With Snow Mountain Virus

NCT07198139
View directory record Official record
Conditions
Norovirus
Interventions
CDI-988, Placebo, Snow Mountain Virus
Drug · Other
Lead sponsor
Cocrystal Pharma, Inc.
Industry
Eligibility
18 Years to 49 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 16, 2026 · Synced Sep 3, 2026, 4:28 PM EDT
Not listed No phase listed Observational

A Multi-Site Clinical Evaluation of the ARIES Norovirus Assay

NCT02092259
View directory record Official record
Conditions
Acute Gastroenteritis
Interventions
Not listed
Lead sponsor
Luminex Corporation
Industry
Eligibility
Not listed
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2014
U.S. locations
5
States / cities
Los Angeles, California • Aurora, Colorado • Indianapolis, Indiana + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2015 · Synced Sep 3, 2026, 4:28 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

New Challenge Pool of Norwalk Virus Inoculum

NCT00138476
View directory record Official record
Conditions
Gastroenteritis Norovirus
Interventions
Placebo, Norwalk Virus
Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 8, 2014 · Synced Sep 3, 2026, 4:28 PM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

Phase I Study to Determine the Optimal Human Challenge Dose for a Norovirus GII.4 Challenge Stock (CIN-1)

NCT02337842
View directory record Official record
Conditions
Gastroenteritis Norovirus
Interventions
Norovirus GII.4 Challenge Pool CIN-1, Placebo
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 2, 2016 · Synced Sep 3, 2026, 4:28 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Long-Term Immunogenicity of the Norovirus GI.1/GII.4 Bivalent Virus-like Particle (VLP) Vaccine (NoV Vaccine) in Adults

NCT03039790
View directory record Official record
Conditions
Healthy Volunteers, Norovirus
Interventions
NoV Vaccine
Biological
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
528 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
9
States / cities
Birmingham, Alabama • Fountain Hills, Arizona • Littleton, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2022 · Synced Sep 3, 2026, 4:28 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Immunogenicity & Safety Study of Adenovirus Type 5 (AD5) Based Oral Norovirus Vaccines

NCT04875676
View directory record Official record
Conditions
Norovirus Infections
Interventions
VXA-G1.1-NN
Biological
Lead sponsor
Vaxart
Industry
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated May 21, 2024 · Synced Sep 3, 2026, 4:28 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1 Placebo-controlled, Randomized Trial of an Adenoviral-vector Based Norovirus Vaccine

NCT02868073
View directory record Official record
Conditions
Norovirus Gastroenteritis
Interventions
VXA-G1.1-NN (high dose) Oral Vaccine Tablet, VXA Placebo Tablets, VXA-G1.1-NN (low dose) Oral Vaccine Tablet
Biological · Other
Lead sponsor
Vaxart
Industry
Eligibility
18 Years to 49 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated May 30, 2018 · Synced Sep 3, 2026, 4:28 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Norovirus Challenge Study

NCT05212168
View directory record Official record
Conditions
Norovirus Infections
Interventions
VXA-G1.1-NN, Placebo Tablets, Norovirus GI.1 Norwalk Virus Inoculum
Biological · Other
Lead sponsor
Vaxart
Industry
Eligibility
18 Years to 49 Years
Enrollment
165 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Nov 4, 2025 · Synced Sep 3, 2026, 4:28 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Optimal Human Dose for GII.2 Norovirus (Snow Mountain) Challenge Studies

NCT02473224
View directory record Official record
Conditions
Gastroenteritis Norovirus
Interventions
Norovirus GII.2 Challenge, Placebo
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 6, 2018 · Synced Sep 3, 2026, 4:28 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Trial of a Norovirus G1.1 and G2.4 Vaccine Administered Orally to Healthy Participants Aged ≥ 18 Years and ≤ 80 Years Old

NCT06944717
View directory record Official record
Conditions
Norovirus Infections
Interventions
VXA-G1.1-NN, VXA-G2.4-NS, VXA G1.1 NN-T, VXA G2.4 NS-T
Biological
Lead sponsor
Vaxart
Industry
Eligibility
18 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 26, 2026 · Synced Sep 3, 2026, 4:28 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Norovirus Bivalent-Vaccine Efficacy Study

NCT01609257
View directory record Official record
Conditions
Prevention From Norovirus Infection
Interventions
Norovirus Bivalent Vaccine, Saline Comparator
Biological
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 49 Years
Enrollment
132 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
5
States / cities
Atlanta, Georgia • Baltimore, Maryland • Rochester, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2019 · Synced Sep 3, 2026, 4:28 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety & Immunogenicity Study of Ad5 Based Oral Norovirus Vaccines

NCT03897309
View directory record Official record
Conditions
Norovirus Infection
Interventions
VXA-G1.1-NN, VXA-G2.4-NS, Placebo Tablets
Biological
Lead sponsor
Vaxart
Industry
Eligibility
18 Years to 49 Years
Enrollment
86 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 20, 2022 · Synced Sep 3, 2026, 4:28 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Viral Infections in Healthy and Immunocompromised Hosts

NCT01306084
View directory record Official record
Conditions
Anogenital Herpes, COVID-19, Herpes Labialis
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
6 Months to 120 Years
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Sep 3, 2026, 4:28 PM EDT
Terminated Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Efficacy and Safety of Two Doses of HIL-214 in Children

NCT05281094
View directory record Official record
Conditions
Gastroenteritis
Interventions
HIL-214, Placebo
Biological
Lead sponsor
HilleVax
Industry
Eligibility
5 Months to 5 Months
Enrollment
3,084 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 9, 2025 · Synced Sep 3, 2026, 4:28 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Ph 1b: Safety & Immunogenicity of Ad5 Based Oral Norovirus Vaccine

NCT04854746
View directory record Official record
Conditions
Norovirus Infections
Interventions
VXA-GI.1.NN, Placebo Tablet
Biological
Lead sponsor
Vaxart
Industry
Eligibility
55 Years to 80 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
3
States / cities
Cypress, California • New Orleans, Louisiana • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Feb 12, 2023 · Synced Sep 3, 2026, 4:28 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of Norovirus Bivalent Virus-Like Particle Vaccine in Healthy Adults

NCT02142504
View directory record Official record
Conditions
Norovirus Prevention
Interventions
Norovirus Bivalent VLP Vaccine, Placebo (Saline)
Biological · Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 49 Years
Enrollment
454 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
10
States / cities
San Diego, California • San Francisco, California • Coral Gables, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2017 · Synced Sep 3, 2026, 4:28 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1, Open-label, Safety and Immunogenicity Study of an Oral Multi-dose Administration Regimen With an Adenoviral-vector Based Tablet Norovirus Vaccine (VXA-G1.1-NN) Administered to Healthy Adult Volunteers

NCT05213728
View directory record Official record
Conditions
Norovirus Infections
Interventions
VXA-G1.1-NN
Biological
Lead sponsor
Vaxart
Industry
Eligibility
18 Years to 55 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Jun 20, 2024 · Synced Sep 3, 2026, 4:28 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Infectivity of Norovirus in Shellfish Treated With High Hydrostatic Pressure Processing-Human Challenge Study

NCT00674336
View directory record Official record
Conditions
Healthy
Interventions
High Hydrostatic Pressure Processing
Procedure
Lead sponsor
Emory University
Other
Eligibility
18 Years to 50 Years
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 18, 2013 · Synced Sep 3, 2026, 4:28 PM EDT